Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients

Francesco Gaudio, Patrizio Mazza, Anna Mele, Giulia Palazzo, Angelo Michele Carella, Mario Delia, Giovanni Pisapia, Domenico Pastore, Nicola Cascavilla, Vincenzo Pavone, Giorgina Specchia

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43% cumulative incidence at 3 years versus 47% in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53%, 3-year overall survival (OS) was 62%, 3-year non-relapse mortality (NRM) was 24%. In the no BV group, the 3-year PFS was 33%, 3-year OS was 44%, and 3-year NRM was 14%. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51% vs. 10%, p = 0.013).

Original languageEnglish
JournalAnnals of Hematology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Survival
Graft vs Host Disease
Disease-Free Survival
Incidence
cAC10-vcMMAE
Mortality
Transplants

Keywords

  • Allogeneic stem cell transplant
  • Brentuximab vedotin
  • Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients. / Gaudio, Francesco; Mazza, Patrizio; Mele, Anna; Palazzo, Giulia; Carella, Angelo Michele; Delia, Mario; Pisapia, Giovanni; Pastore, Domenico; Cascavilla, Nicola; Pavone, Vincenzo; Specchia, Giorgina.

In: Annals of Hematology, 01.01.2019.

Research output: Contribution to journalArticle

Gaudio, Francesco ; Mazza, Patrizio ; Mele, Anna ; Palazzo, Giulia ; Carella, Angelo Michele ; Delia, Mario ; Pisapia, Giovanni ; Pastore, Domenico ; Cascavilla, Nicola ; Pavone, Vincenzo ; Specchia, Giorgina. / Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients. In: Annals of Hematology. 2019.
@article{513bd91cda1547ca97faff1008ae462b,
title = "Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients",
abstract = "This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43{\%} cumulative incidence at 3 years versus 47{\%} in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53{\%}, 3-year overall survival (OS) was 62{\%}, 3-year non-relapse mortality (NRM) was 24{\%}. In the no BV group, the 3-year PFS was 33{\%}, 3-year OS was 44{\%}, and 3-year NRM was 14{\%}. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51{\%} vs. 10{\%}, p = 0.013).",
keywords = "Allogeneic stem cell transplant, Brentuximab vedotin, Hodgkin lymphoma",
author = "Francesco Gaudio and Patrizio Mazza and Anna Mele and Giulia Palazzo and Carella, {Angelo Michele} and Mario Delia and Giovanni Pisapia and Domenico Pastore and Nicola Cascavilla and Vincenzo Pavone and Giorgina Specchia",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00277-019-03662-6",
language = "English",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients

AU - Gaudio, Francesco

AU - Mazza, Patrizio

AU - Mele, Anna

AU - Palazzo, Giulia

AU - Carella, Angelo Michele

AU - Delia, Mario

AU - Pisapia, Giovanni

AU - Pastore, Domenico

AU - Cascavilla, Nicola

AU - Pavone, Vincenzo

AU - Specchia, Giorgina

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43% cumulative incidence at 3 years versus 47% in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53%, 3-year overall survival (OS) was 62%, 3-year non-relapse mortality (NRM) was 24%. In the no BV group, the 3-year PFS was 33%, 3-year OS was 44%, and 3-year NRM was 14%. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51% vs. 10%, p = 0.013).

AB - This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43% cumulative incidence at 3 years versus 47% in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53%, 3-year overall survival (OS) was 62%, 3-year non-relapse mortality (NRM) was 24%. In the no BV group, the 3-year PFS was 33%, 3-year OS was 44%, and 3-year NRM was 14%. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51% vs. 10%, p = 0.013).

KW - Allogeneic stem cell transplant

KW - Brentuximab vedotin

KW - Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85062903858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062903858&partnerID=8YFLogxK

U2 - 10.1007/s00277-019-03662-6

DO - 10.1007/s00277-019-03662-6

M3 - Article

C2 - 30868307

AN - SCOPUS:85062903858

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -